Safety and efficacy of an initial regimen of atazanavir + ritonavir + the abacavir/lamivudine fixed-dose combination tablet (ABC/3TC FDC) for 36 weeks followed by simplification to atazanavir with ABC/3TC FDC or maintenance of the initial regimen for an additional 48 weeks in antiretroviral-naive HIV-1 infected HLA-B5701 negative subjects

Trial Profile

Safety and efficacy of an initial regimen of atazanavir + ritonavir + the abacavir/lamivudine fixed-dose combination tablet (ABC/3TC FDC) for 36 weeks followed by simplification to atazanavir with ABC/3TC FDC or maintenance of the initial regimen for an additional 48 weeks in antiretroviral-naive HIV-1 infected HLA-B5701 negative subjects

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Jun 2015

At a glance

  • Drugs Atazanavir (Primary) ; Lamivudine/abacavir (Primary) ; Ritonavir (Primary)
  • Indications HIV-1 infections
  • Focus Registrational; Therapeutic Use
  • Acronyms ARIES
  • Sponsors ViiV Healthcare
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 20 Jul 2011 Long-term extension study results presented at the 6th International AIDS Society Conference on HIV Pathogenesis and Treatment.
    • 24 Nov 2010 Actual end date (Jul 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top